Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

InMed taps ATERA for 3D skin models
September 2017
SHARING OPTIONS:

VANCOUVER—Biopharmaceutical company InMed Pharmaceuticals Inc. and ATERA SAS have struck up a research and development collaboration under which ATERA will produce 3D human skin models of epidermolysis bullosa (EB) for evaluating the in-vitro drug efficacy of INM-750. The compound is InMed’s lead candidate, a proprietary, topical cannabinoid product candidate being developed as a therapy for EB and potentially other dermatological and wound-healing indications. ATERA will also assess the effectiveness of INM-750 when applied topically, using in-vitro 3D reconstructed human full thickness skin models of normal and EB-derived cells to determine the effects at the ultra-structural cellular and molecular levels. Preclinical models have shown that INM-750 has significant potential for addressing symptomatic improvement of EB in terms of accelerated wound healing and reducing itch, pain and inflammation.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.